This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tuomilehto J et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350
Nathan DM et al. (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30: 753–759
Sladek R et al. (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445: 881–885
Chiasson JL et al. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072–2077
DECODE Study Group (1998) Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ 317: 371–375
Torgerson JS et al. (2004) Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27: 155–161
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096–1105
Kahn SE et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443
Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471
ORIGIN Trial Investigators (2008) Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 155: 26–32
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
WA Hsueh has declared associations with the following companies: GlaxoSmithKline (consultant and grant/research support), Merck (speakers bureau) and Novartis (consultant and grant/research support).
Y Handelsman has declared associations with the following companies: Amylin (speakers bureau), AstraZeneca (speakers bureau), Bristol-Myers Squibb (speakers bureau), GlaxoSmithKline (consultant and speakers bureau), Merck (speakers bureau), Novartis (speakers bureau), and Sankyo (consultant and grant/research support).
Rights and permissions
About this article
Cite this article
Hsueh, W., Handelsman, Y. Pharmacologic treatment options for prediabetes. Nat Rev Endocrinol 4, 380–381 (2008). https://doi.org/10.1038/ncpendmet0842
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0842